|
|
|
|
Expression and prognostic value of VEGFR-2,PDGFR-β,and c-Met in advanced hepatocellular carcinoma
|
|
|
|
|
|
|
|
نویسنده
|
chu j.s. ,ge f.j. ,zhang b. ,wang y. ,silvestris n. ,liu l.j. ,zhao c.h. ,lin l. ,brunetti a.e. ,fu y.l. ,wang j. ,paradiso a. ,xu j.m.
|
|
منبع
|
journal of experimental and clinical cancer research - 2013 - دوره : 32 - شماره : 1
|
|
چکیده
|
Background: we explore the clinical and prognostic significance of expression of vascular endothelial growth factor receptor (vegfr)-2,platelet-derived growth factor receptor (pdgfr)-β,and c-met in patients with hepatocellular carcinoma (hcc). methods. the expression of vegfr-2,pdgfr-β,and c-met were determined by immunohistochemical examination of the tissues of 93 hcc patients. the relationships of these markers with clinicopathological factors and prognosis were then analyzed. results: high expression of vegfr-2,pdgfr-β,and c-met was found in 86%,19.4%,and 80.6% of patients,respectively. expression of vegfr-2 correlated with gender (p = 0.044),hepatitis b surface antigen positivity (p = 0.024),degree of tumor differentiation (p = 0.023),and hepatic cirrhosis (p = 0.026). expression of pdgfr-β correlated with alpha-fetoprotein level (p = 0.029),tumor size (p = 0.033),and hepatic cirrhosis (p = 0.023). no significant correlations were identified between expression of c-met and clinicopathological factors. expression of pdgfr-β correlated with overall survival (p = 0.046) and expression of c-met correlated with progression-free survival (p = 0.01). conclusions: we found that in patients with hcc,high expression of vegfr-2 correlates with chronic hepatitis b virus infection and hepatic cirrhosis. high expression of pdgfr-β is a predictor of poor prognosis. high expression of c-met may predict therapeutic effectiveness of sorafenib in hcc patients. © 2013 chu et al.; licensee biomed central ltd.
|
|
کلیدواژه
|
c-Met; Hepatocellular carcinoma; PDGFR-β; Sorafenib; Survival analysis; VEGFR-2
|
|
آدرس
|
affiliated hospital cancer center,academy of military medical sciences,no.8 dong da street,fengtai district,beijing 100071,china,department of oncology,jiujiang cancer hospital,jiujiang 332000,jiangxi, China, affiliated hospital cancer center,academy of military medical sciences,no.8 dong da street,fengtai district,beijing 100071, China, affiliated hospital,department of pathology,academy of military medical science,no.8 dong da street,fengtai district,beijing 100071, China, affiliated hospital cancer center,academy of military medical sciences,no.8 dong da street,fengtai district,beijing 100071, China, medical oncology unit,national cancer institute giovanni paolo ii,bari, Italy, affiliated hospital cancer center,academy of military medical sciences,no.8 dong da street,fengtai district,beijing 100071, China, affiliated hospital cancer center,academy of military medical sciences,no.8 dong da street,fengtai district,beijing 100071, China, affiliated hospital cancer center,academy of military medical sciences,no.8 dong da street,fengtai district,beijing 100071, China, scientific direction,national cancer institute giovanni paolo ii,viale orazio flacco,65,70124 bari, Italy, affiliated hospital cancer center,academy of military medical sciences,no.8 dong da street,fengtai district,beijing 100071, China, department of oncology,jiujiang cancer hospital,jiujiang 332000,jiangxi, China, scientific direction,national cancer institute giovanni paolo ii,viale orazio flacco,65,70124 bari, Italy, affiliated hospital cancer center,academy of military medical sciences,no.8 dong da street,fengtai district,beijing 100071, China
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Authors
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|